| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 09/05/2002 | DE10107663A1 Testosteronhaltiges transdermales therapeutisches System und Verfahren zu seiner Herstellung Testosterone-containing transdermal therapeutic system and process for its preparation |
| 09/04/2002 | EP1236468A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders |
| 09/04/2002 | EP1235860A2 G-protein coupled receptors |
| 09/04/2002 | EP1235850A1 Unsaturated 14,15-cyclopropane-androstanes, a method for their production and pharmaceutical compositions containing these compounds |
| 09/04/2002 | EP1235846A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235825A1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 09/04/2002 | EP1235824A1 Vitamin d analogues |
| 09/04/2002 | EP1235812A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 09/04/2002 | EP1235797A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 09/04/2002 | EP1235777A2 Vitamin d analogues |
| 09/04/2002 | EP1235776A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 09/04/2002 | EP1235618A2 Bioconjugation in vivo to pulmonary or blood components |
| 09/04/2002 | EP1235594A2 Inhibition of secretion from non-neuronal cells |
| 09/04/2002 | EP1235574A2 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 09/04/2002 | EP1235571A1 Use of melatonin for treating androgenetic and diffuse alopecia |
| 09/04/2002 | EP0930879B1 Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation |
| 09/04/2002 | CN1367793A Neuromedin B and somatostatin receptor agonists |
| 09/04/2002 | CN1367792A Somatostatin agonists |
| 09/04/2002 | CN1367778A Novel carboxylic acid derivatives with 5,6 substitutedpyrimidine ring, their production and utilization thereof as endothelin receptor antagonists |
| 09/04/2002 | CN1367698A Administration of non-oral androgenic steroids to women |
| 09/04/2002 | CN1367687A Calcilytic compounds |
| 09/04/2002 | CN1367169A Substituted 6,6-Hetero-dicycloderivative |
| 09/03/2002 | US6444223 Fineness particle size; sustained release of drug |
| 08/29/2002 | WO2002066649A2 ANTI-INTERFERON-α ANTIBODIES |
| 08/29/2002 | WO2002066646A2 Neurotransmission-associated proteins |
| 08/29/2002 | WO2002066635A1 Transgenic animal having drug metabolism enzyme gene and utilization thereof |
| 08/29/2002 | WO2002066477A2 Imidazopyridines |
| 08/29/2002 | WO2002066475A2 Tricyclic androgen receptor modulator compounds |
| 08/29/2002 | WO2002066462A1 Pyrazole derivatives against tgf overexpression |
| 08/29/2002 | WO2002066461A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/29/2002 | WO2002066459A1 Indole derivatives and their use as gnrh antagonists |
| 08/29/2002 | WO2002066437A1 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone |
| 08/29/2002 | WO2002066078A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066077A2 Modulated release particles for aerosol delivery |
| 08/29/2002 | WO2002066064A1 Use of galanin-like peptide |
| 08/29/2002 | WO2002066040A2 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 08/29/2002 | WO2002066018A2 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 08/29/2002 | WO2002034286B1 Methods for treating endocrine disorders |
| 08/29/2002 | WO2002016426A3 Coaster, a human coactivator of steroid receptors |
| 08/29/2002 | WO2002000227A3 Use of lanthanum compounds for the treatment of bone diseases |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001092497A3 Human pancreatic islet glucose-6-phosphatase |
| 08/29/2002 | WO2000066104A9 Ace-2 inhibiting compounds and methods of use thereof |
| 08/29/2002 | US20020120100 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents |
| 08/29/2002 | US20020119988 Modulators of TNF-alpha signaling |
| 08/29/2002 | US20020119964 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| 08/29/2002 | US20020119186 Establishing a drug depot in tissues under the user's skin surface by applying a transdermal drug delivery system on a user's skin; allowing transdermal drug delivery system to be applied on skin area without heating; placing heating source |
| 08/29/2002 | US20020117170 Compositions and methods for the pulmonary delivery of aerosolized macromolecules |
| 08/29/2002 | CA2438709A1 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2437161A1 Anti-interferon-.alpha. antibodies |
| 08/28/2002 | EP1234821A1 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient |
| 08/28/2002 | EP1234574A1 Hair growth stimulant |
| 08/28/2002 | EP1233975A1 29 human secreted proteins |
| 08/28/2002 | EP1233965A1 Isoquinoline and quinazoline derivatives for the treatment of cns disorders |
| 08/28/2002 | EP1233959A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 08/28/2002 | EP1233781A1 Assays and therapies for latent viral infection |
| 08/28/2002 | EP1233777A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233774A1 Urotensin-ii analogs |
| 08/28/2002 | EP1233773A1 Mixture of pomegranate seed oil and juice products |
| 08/28/2002 | EP1233756A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 08/28/2002 | EP0918759B1 Novel thiazolidone-2 derivatives, 4-diketone substituted, method for obtaining them and pharmaceutical compositions containing same |
| 08/28/2002 | EP0869785B1 4-hydroxycoumarin-3-carboxamides for the treatment of non-insulin dependent diabetes mellitus |
| 08/28/2002 | EP0829011B1 Inhibition of amylin release |
| 08/28/2002 | EP0794961B1 Lhrh antagonist peptides |
| 08/28/2002 | CN1366520A Medicine |
| 08/28/2002 | CN1365984A Parathyroid hormone analog and its preparing process by recombination |
| 08/28/2002 | CN1365823A Active full-component wheat spear extract and its microcapsule and preparing process |
| 08/27/2002 | US6441193 Intermediates such as 1-(2-(4-(6-methoxy-3,4-dihydronaphtha-len-1-yl)phenoxy)ethyl)pyrrolidine and compounds such as cis-6-phenyl-5-(4-(2-pyrrolidin-1-ylethoxy)phenyl)-5,6,7,8 -tetrahydronaphthalen-2-ol, hydrobromide salt |
| 08/27/2002 | US6441015 Tetrazole compounds as thyroid receptor ligands |
| 08/27/2002 | US6440975 Amino acid derivatives, the preparation and use thereof as endothelin antagonists |
| 08/27/2002 | US6440966 Benzenesulfonamide derivatives and their use as MEK inhibitors |
| 08/27/2002 | US6440421 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| 08/27/2002 | US6440413 Selectively destroying subunit a without destroying subunit b of cholera toxin; enzyme with preponderance of exocellular proteinase produced by a culture of streptomyces fradiae; hyperviscosity of intestinal, bronchial and/or genital mucus |
| 08/22/2002 | WO2002064795A2 Putative human enzymes |
| 08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
| 08/22/2002 | WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | WO2002064592A1 Tricyclic crf receptor antagonists |
| 08/22/2002 | WO2002064586A2 Heterocyclic inhibitors of erk2 and uses thereof |
| 08/22/2002 | WO2002064580A1 Lactone compounds as novel photoinitiators |
| 08/22/2002 | WO2002064550A1 Glucocorticoid receptor modulators |
| 08/22/2002 | WO2002064543A2 Novel succinate salt of o-desmethyl-venlafaxine |
| 08/22/2002 | WO2002064146A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
| 08/22/2002 | WO2002064138A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 08/22/2002 | WO2002064094A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | WO2002064093A2 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| 08/22/2002 | WO2002064083A2 Synthesis of 3-amino-thalidomide and its enantiomers |
| 08/22/2002 | WO2002032893A3 Piperidine compounds as anti-allergic |
| 08/22/2002 | WO2002032377A3 Estrogen receptor modulators |
| 08/22/2002 | WO2002015959A3 Compounds and compositions for delivering active agents |
| 08/22/2002 | WO2002008250A3 Ghrelin antagonists |
| 08/22/2002 | US20020115856 Selective cyclooxygenase-2 (COX-2) inhibitors; for example, 1-(5-Methanesulfonyl-pyridin-2-yl)-7-methoxy-3-trifluoromethyl-4,5-dihydro -1H-benzo(g)indazole |
| 08/22/2002 | US20020115853 6-(3-nitrophenyl)-3H-benzooxazol-2-one for example; contraceptives, treating hormone dependent tumors, endometriosis; progesterone receptor agonists and antagonists |
| 08/22/2002 | US20020115676 Therapy for andropause using estrogen agonists / antagonists and testosterone |
| 08/22/2002 | US20020115615 A peptide compound, where a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH is replaced; anticarcinogenic and -tumor agents; hormone inhibitors; urogenital disorders |
| 08/22/2002 | US20020115603 Methods and compositions for the treatment of peripheral artery disease |
| 08/22/2002 | US20020115205 Receptor protein for use in the treatment of cancer, infections, psoraisis, asthma, allergies, viral diseases, arteriosclerosis, gland, eye, autoimmune, nervous system and psychological disorders |
| 08/22/2002 | US20020114836 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 08/22/2002 | US20020114786 Pharmaceutical preparations comprising soybean isoflavone extracts and probiotic microogranisms |
| 08/22/2002 | US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases |